Nelarabine in the treatment of refractory T-cell malignancies
about
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.The double-edged sword: Neurotoxicity of chemotherapy.Nelarabine associated myotoxicity and rhabdomyolysis.A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant.Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
P2860
Nelarabine in the treatment of refractory T-cell malignancies
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Nelarabine in the treatment of refractory T-cell malignancies
@ast
Nelarabine in the treatment of refractory T-cell malignancies
@en
Nelarabine in the treatment of refractory T-cell malignancies
@nl
type
label
Nelarabine in the treatment of refractory T-cell malignancies
@ast
Nelarabine in the treatment of refractory T-cell malignancies
@en
Nelarabine in the treatment of refractory T-cell malignancies
@nl
prefLabel
Nelarabine in the treatment of refractory T-cell malignancies
@ast
Nelarabine in the treatment of refractory T-cell malignancies
@en
Nelarabine in the treatment of refractory T-cell malignancies
@nl
P2093
P2860
P3181
P356
P1476
Nelarabine in the treatment of refractory T-cell malignancies
@en
P2093
Amy Stockert
Andrew M Roecker
David F Kisor
P2860
P304
P3181
P356
10.4137/CMO.S4364
P407
P577
2010-01-01T00:00:00Z